ADMA Biologics, Inc. (ADMA) Financial Statements
ADMA Biologics, Inc. (ADMA) reported trailing twelve-month revenue of $512.3M (up 8.0% year on year) and net income of $169.0M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $116.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ADMAADMA Biologics, Inc.Follow ADMA — free
—
Price chart with a free account
- Market cap
- 2.4B
- P/E TTM
- 15.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.1 | 3.1 | 5.9 | 7.2 | 10.7 | 22.8 | 17.0 | 29.3 | 42.2 | 80.9 | 154.1 | 258.2 | 426.5 | 510.2 | 512.3 | |
| Gross profit | 0.4 | 1.0 | 2.2 | 2.9 | 4.3 | -6.4 | -25.2 | -10.2 | -19.1 | 1.2 | 35.3 | 88.9 | 219.6 | 292.8 | 331.5 | |
| Research & development | 3.5 | 9.3 | 9.5 | 7.0 | 7.7 | 5.6 | 3.9 | 2.3 | 5.9 | 3.6 | 3.6 | 3.3 | 1.8 | 4.8 | 11.5 | |
| Operating income | -7.9 | -15.0 | -16.0 | -15.5 | -17.3 | -39.3 | -60.3 | -41.4 | -64.9 | -58.4 | -39.4 | 21.6 | 139.0 | 191.4 | 224.5 | |
| Pre-tax income | -7.9 | -15.5 | -17.4 | -18.0 | -19.5 | -43.8 | -65.7 | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 | 125.7 | 182.7 | 216.5 | |
| Income tax | — | 0.0 | -0.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -72.0 | 35.7 | 47.5 | |
| Net income | -7.3 | -15.5 | -16.8 | -18.0 | -19.5 | -43.8 | -65.7 | -48.3 | -75.7 | -71.6 | -65.9 | -28.2 | 197.7 | 146.9 | 169.0 | |
| Diluted EPS ($) | -1.39 | -2.38 | -1.81 | -1.73 | -1.61 | -1.91 | -1.45 | -0.89 | -0.88 | -0.51 | -0.33 | -0.13 | 0.81 | 0.60 | 0.70 | |
| Diluted shares (mn) | — | — | — | — | — | — | — | — | — | 139.6 | 197.9 | 224.0 | 243.3 | 244.9 | — |
USD millions · SEC XBRL
ADMA Biologics, Inc. — questions
- What is ADMA Biologics, Inc.'s revenue?
- $512.3M over the twelve months to 2026-06-30, up 8.0% year on year, from its 10-Q and 10-K filings.
- What is ADMA Biologics, Inc.'s net income?
- $169.0M over the twelve months to 2026-06-30.
- What is ADMA Biologics, Inc.'s free cash flow?
- $116.5M over the twelve months to 2026-06-30.
- What are ADMA Biologics, Inc.'s diluted earnings per share?
- $0.70 over the twelve months to 2026-06-30.
Every figure on this page comes from ADMA Biologics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.